CA2467046A1 - Procede de fabrication de leucocytes phagocytaires mononucleaires humains - Google Patents
Procede de fabrication de leucocytes phagocytaires mononucleaires humains Download PDFInfo
- Publication number
- CA2467046A1 CA2467046A1 CA002467046A CA2467046A CA2467046A1 CA 2467046 A1 CA2467046 A1 CA 2467046A1 CA 002467046 A CA002467046 A CA 002467046A CA 2467046 A CA2467046 A CA 2467046A CA 2467046 A1 CA2467046 A1 CA 2467046A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- activated
- mononuclear phagocytic
- phagocytic leukocytes
- segments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract 26
- 210000000265 leukocyte Anatomy 0.000 title claims abstract 22
- 230000000242 pagocytic effect Effects 0.000 title claims abstract 22
- 238000004519 manufacturing process Methods 0.000 title claims abstract 3
- 238000002659 cell therapy Methods 0.000 claims abstract 12
- 210000004207 dermis Anatomy 0.000 claims abstract 12
- 210000003491 skin Anatomy 0.000 claims abstract 11
- 210000001616 monocyte Anatomy 0.000 claims abstract 10
- 230000003376 axonal effect Effects 0.000 claims abstract 4
- 230000001737 promoting effect Effects 0.000 claims abstract 4
- 238000011534 incubation Methods 0.000 claims abstract 3
- 208000010125 myocardial infarction Diseases 0.000 claims abstract 3
- 230000008929 regeneration Effects 0.000 claims abstract 3
- 238000011069 regeneration method Methods 0.000 claims abstract 3
- 238000005406 washing Methods 0.000 claims abstract 3
- 230000029663 wound healing Effects 0.000 claims abstract 3
- 210000004369 blood Anatomy 0.000 claims abstract 2
- 239000008280 blood Substances 0.000 claims abstract 2
- 238000005119 centrifugation Methods 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims 27
- 238000002360 preparation method Methods 0.000 claims 11
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 10
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 10
- 239000003242 anti bacterial agent Substances 0.000 claims 9
- 229940088710 antibiotic agent Drugs 0.000 claims 9
- 239000002609 medium Substances 0.000 claims 8
- 230000028327 secretion Effects 0.000 claims 6
- 102000004889 Interleukin-6 Human genes 0.000 claims 5
- 108090001005 Interleukin-6 Proteins 0.000 claims 5
- 208000027418 Wounds and injury Diseases 0.000 claims 5
- 210000001519 tissue Anatomy 0.000 claims 5
- 102000000589 Interleukin-1 Human genes 0.000 claims 4
- 108010002352 Interleukin-1 Proteins 0.000 claims 4
- 239000012737 fresh medium Substances 0.000 claims 4
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 3
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 3
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 3
- 108010031099 Mannose Receptor Proteins 0.000 claims 3
- 206010040943 Skin Ulcer Diseases 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- 239000002158 endotoxin Substances 0.000 claims 3
- 239000008187 granular material Substances 0.000 claims 3
- 230000036512 infertility Effects 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 238000007491 morphometric analysis Methods 0.000 claims 3
- 210000000278 spinal cord Anatomy 0.000 claims 3
- 241000894006 Bacteria Species 0.000 claims 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 claims 2
- 206010052428 Wound Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 210000002615 epidermis Anatomy 0.000 claims 2
- 230000007717 exclusion Effects 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000035876 healing Effects 0.000 claims 2
- 230000001338 necrotic effect Effects 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 238000002791 soaking Methods 0.000 claims 2
- 238000010186 staining Methods 0.000 claims 2
- 230000035899 viability Effects 0.000 claims 2
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical group C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 claims 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 1
- 229930182566 Gentamicin Natural products 0.000 claims 1
- 238000003794 Gram staining Methods 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 239000012980 RPMI-1640 medium Substances 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 108010059993 Vancomycin Proteins 0.000 claims 1
- 230000007844 axonal damage Effects 0.000 claims 1
- 230000003833 cell viability Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 238000005520 cutting process Methods 0.000 claims 1
- 210000004395 cytoplasmic granule Anatomy 0.000 claims 1
- 238000005202 decontamination Methods 0.000 claims 1
- 230000003588 decontaminative effect Effects 0.000 claims 1
- 239000008367 deionised water Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 229960002518 gentamicin Drugs 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- 238000010257 thawing Methods 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 229960003165 vancomycin Drugs 0.000 claims 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/17—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1323—Adult fibroblasts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
L'invention concerne un procédé de fabrication de leucocytes phagocytaires mononucléaires humains consistant à incuber les monocytes isolés d'un échantillon sanguin d'un sujet et des fragments de peau du même sujet, à enlever les fragments de derme du mélange d'incubation et à sédimenter les leucocytes phagocytaires mononucléaires activés ainsi obtenus par centrifugation, lavage et resuspension des leucocytes phagocytaires activés dans le milieu, enfin à procéder à une évaluation pour savoir si la culture est appropriée pour être administrée à un humain. Des produits de thérapie cellulaire sont fabriqués à partir des cultures obtenues, lesquels produits de thérapie sont utiles pour la promotion de la régénérescence axonale dans le système nerveux central, la cicatrisation des plaies et le traitement de l'infarctus du myocarde.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33178001P | 2001-11-21 | 2001-11-21 | |
| US60/331,780 | 2001-11-21 | ||
| PCT/IL2002/000930 WO2003044037A2 (fr) | 2001-11-21 | 2002-11-21 | Procede de fabrication de leucocytes phagocytaires mononucleaires humains |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2467046A1 true CA2467046A1 (fr) | 2003-05-30 |
| CA2467046C CA2467046C (fr) | 2011-07-19 |
Family
ID=23295342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2467046A Expired - Fee Related CA2467046C (fr) | 2001-11-21 | 2002-11-21 | Procede de fabrication de leucocytes phagocytaires mononucleaires humains |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8377692B2 (fr) |
| EP (1) | EP1456355A4 (fr) |
| JP (2) | JP2005519585A (fr) |
| KR (2) | KR20100087781A (fr) |
| CN (1) | CN1615357A (fr) |
| AU (1) | AU2002353465B2 (fr) |
| CA (1) | CA2467046C (fr) |
| IL (2) | IL162094A0 (fr) |
| MX (1) | MXPA04004813A (fr) |
| NZ (1) | NZ533033A (fr) |
| WO (1) | WO2003044037A2 (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060210543A1 (en) * | 2005-03-21 | 2006-09-21 | Jonathan Leor | Method of treating infarcted myocardium |
| US9220813B2 (en) | 2005-04-18 | 2015-12-29 | Holy Cross Hospital, Inc. | Cell therapy for limiting overzealous inflammatory reactions in tissue healing |
| US8637005B2 (en) | 2005-11-07 | 2014-01-28 | Amorcyte, Inc. | Compositions and methods of vascular injury repair |
| US20110076255A1 (en) | 2005-11-07 | 2011-03-31 | Pecora Andrew L | Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency |
| DK2441461T3 (da) * | 2005-11-07 | 2014-07-28 | Amorcyte Inc | Sammensætninger og fremgangsmåder til reparation af vaskulær skade |
| RU2535966C2 (ru) * | 2008-09-12 | 2014-12-20 | Криопрашис Криобиоложия Лтда. | Клеточная терапия ишемической ткани |
| WO2010065601A1 (fr) * | 2008-12-03 | 2010-06-10 | Amorcyte, Inc. | Compositions améliorant la perfusion d’une zone d’infarctus et procédés de réparation de lésion vasculaire |
| CN102438635B (zh) * | 2009-03-05 | 2014-09-17 | 马克罗柯尔有限公司 | 活化的白细胞组合物 |
| US8574902B2 (en) | 2009-03-05 | 2013-11-05 | Macrocure Ltd. | Activated leukocyte composition and uses for wound healing |
| JP6061345B2 (ja) * | 2010-08-27 | 2017-01-18 | ユニヴァーシティ・オヴ・マイアミ | 心臓修復のための骨髄由来ｃｄ２７１前駆細胞 |
| BR112013005610A2 (pt) | 2010-09-09 | 2019-09-24 | Macrocure Ltd | sobrenadante condicionado de leucócito, alcs, método para o tratamento de uma ferida, método para a inibição do surgimento de infecção em uma ferida, método, sobrenadante e produto |
| BR112014014560A8 (pt) | 2011-12-14 | 2017-07-04 | Yeda Res & Dev | subpopulação de monócitos humanos para tratamento de lesões do sistema nervoso central |
| EP2662085A1 (fr) * | 2012-05-11 | 2013-11-13 | Humboldt-Universität zu Berlin | Macrophages régulateurs et leurs utilisations |
| CN102703597B (zh) * | 2012-06-20 | 2013-10-30 | 安徽信灵检验医学科技有限公司 | 血液白细胞分离液及其制作方法、真空采血管 |
| EP2999479B1 (fr) | 2013-05-22 | 2021-01-06 | Yeda Research and Development Co., Ltd. | Sous-population de monocytes humains pour le traitement de maladies et de troubles oculaires |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4086057A (en) | 1976-07-28 | 1978-04-25 | William Clinton Everett | Ultrasonic disinfection system |
| US5292655A (en) * | 1990-01-29 | 1994-03-08 | Wille Jr John J | Method for the formation of a histologically-complete skin substitute |
| JP3543869B2 (ja) * | 1995-03-07 | 2004-07-21 | 株式会社メニコン | 培養皮膚およびその製造法 |
| US6267955B1 (en) * | 1995-09-15 | 2001-07-31 | Yeda Research And Development Co. Ltd. | Mononuclear phagocytes and their use to promote axonal regeneration |
| US5800812A (en) * | 1995-09-15 | 1998-09-01 | Yeda Research And Development Co. Ltd. | Methods of use of mononuclear phagocytes to promote axonal regeneration |
| US6060515A (en) * | 1997-01-24 | 2000-05-09 | The Regents Of The University Of California | Treatment of skin conditions by use of PPARα activators |
| AU5610398A (en) * | 1997-02-28 | 1998-09-18 | Warner-Lambert Company | Method of treating or preventing septic shock by administering a mek inhibitor |
| WO1999050391A1 (fr) * | 1998-03-30 | 1999-10-07 | I.D.M. Immuno-Designed Molecules | Cellules derivees de monocytes stimules, leur preparation et leurs utilisations |
| US6893462B2 (en) * | 2000-01-11 | 2005-05-17 | Regeneration Technologies, Inc. | Soft and calcified tissue implants |
| US20030109583A1 (en) * | 2001-07-25 | 2003-06-12 | Raju Bore G. | Administration of negamycin or deoxynegamycin for the treatment of bacterial infections |
-
2002
- 2002-11-21 KR KR1020107016499A patent/KR20100087781A/ko not_active Ceased
- 2002-11-21 MX MXPA04004813A patent/MXPA04004813A/es active IP Right Grant
- 2002-11-21 KR KR1020047007695A patent/KR101001119B1/ko not_active Expired - Fee Related
- 2002-11-21 CN CNA028271440A patent/CN1615357A/zh active Pending
- 2002-11-21 CA CA2467046A patent/CA2467046C/fr not_active Expired - Fee Related
- 2002-11-21 JP JP2003545673A patent/JP2005519585A/ja not_active Withdrawn
- 2002-11-21 AU AU2002353465A patent/AU2002353465B2/en not_active Ceased
- 2002-11-21 WO PCT/IL2002/000930 patent/WO2003044037A2/fr not_active Ceased
- 2002-11-21 EP EP02788490A patent/EP1456355A4/fr not_active Ceased
- 2002-11-21 IL IL16209402A patent/IL162094A0/xx active IP Right Grant
- 2002-11-21 US US10/496,352 patent/US8377692B2/en not_active Expired - Fee Related
- 2002-11-21 NZ NZ533033A patent/NZ533033A/en not_active IP Right Cessation
-
2004
- 2004-05-20 IL IL162094A patent/IL162094A/en not_active IP Right Cessation
-
2010
- 2010-01-29 JP JP2010018379A patent/JP5087094B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1456355A2 (fr) | 2004-09-15 |
| NZ533033A (en) | 2006-01-27 |
| JP2010100653A (ja) | 2010-05-06 |
| CA2467046C (fr) | 2011-07-19 |
| WO2003044037A3 (fr) | 2004-04-08 |
| CN1615357A (zh) | 2005-05-11 |
| JP2005519585A (ja) | 2005-07-07 |
| JP5087094B2 (ja) | 2012-11-28 |
| IL162094A0 (en) | 2005-11-20 |
| KR20040076860A (ko) | 2004-09-03 |
| AU2002353465A1 (en) | 2003-06-10 |
| KR20100087781A (ko) | 2010-08-05 |
| WO2003044037A2 (fr) | 2003-05-30 |
| MXPA04004813A (es) | 2004-08-11 |
| KR101001119B1 (ko) | 2010-12-14 |
| US20050129663A1 (en) | 2005-06-16 |
| US8377692B2 (en) | 2013-02-19 |
| EP1456355A4 (fr) | 2005-05-25 |
| AU2002353465B2 (en) | 2008-10-16 |
| IL162094A (en) | 2011-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230405180A1 (en) | Mesenchymal stem cell-hydrogel-biodegradable or mesenchymal stem cell-hydrogel-undegradable support composition for skin regeneration or wound healing | |
| CA2467046A1 (fr) | Procede de fabrication de leucocytes phagocytaires mononucleaires humains | |
| EP2970882B1 (fr) | Matrice de collagène repeuplée de cellules pour réparation et régénération des tissus mous | |
| EP3294356B1 (fr) | Compositions comprenant des cellules souches mésenchymateuses et leurs utilisations | |
| US20100303770A1 (en) | Methods for culturing dermal cells for treatment of skin injuries such as burns | |
| KR101926331B1 (ko) | 수포성 표피박리증 완화 또는 개선용 중간엽줄기세포-하이드로겔-생분해성 또는 중간엽줄기세포-하이드로겔-비분해성 지지체 조성물 | |
| JP2005519585A5 (fr) | ||
| Long et al. | Decellularized extracellular matrix (d-ECM): the key role of the inflammatory process in pre-regeneration after implantation | |
| JP2018515211A5 (fr) | ||
| AU2023206197B2 (en) | Enhanced multipotent cells and microvascular tissue and methods of use thereof | |
| Razavi et al. | Application of novel strategies in chronic wound management with focusing on pressure ulcers: new perspective | |
| Seland et al. | Transplantation of acellular dermis and keratinocytes cultured on porous biodegradable microcarriers into full-thickness skin injuries on athymic rats | |
| CN113230454B (zh) | 一种可诱导骨再生的生物膜及其制备方法和应用 | |
| WO2019035925A1 (fr) | Composition et méthode pour traiter une affection cutanée | |
| EP4435092A1 (fr) | Matériau stromal pour l'encapsulation de cellules, son procédé de préparation et son application | |
| CN103140229A (zh) | 抗肿瘤/癌异源非细胞胶原制剂及其用途 | |
| US20210015973A1 (en) | Human nipple areolar complex extracellular matrix scaffold and methods relating thereto | |
| JP7213479B2 (ja) | 皮膚保護剤 | |
| KARADAĞ | CURRENT AESTHETIC APPLICATIONS OF ADIPOSE-DERIVED STEM CELLS | |
| CN120290448A (zh) | 一种用于细胞扩增的基质支架及应用 | |
| JP2024518142A (ja) | 皮膚瘢痕の治療 | |
| MacNeil | Tissue Engineered Skin Comes of Age? | |
| HK1247862B (en) | Compositions comprising mesenchymal stem cells and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20191121 |